Howard Burris, MD from Sarah Cannon, Nashville, TN discusses TGR-1202 for chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL). TGR-1202 is a PI3K delta inhibitor and Dr Burris discusses how it may be the third compound in this area that will be used in the clinic next to idelalisib and IPI-145. TGR-1202 is well tolerated and is used as a single agent and in combination.
Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.
TGR-1202 in CLL and Non-Hodgkin lymphoma
